Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Rhea-AI Summary

Sagimet Biosciences (Nasdaq: SGMT) announced management will participate in two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 at 10:00 AM ET and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 9:20 AM ET.

Both fireside chats will be webcast in the Investors & Media section at www.sagimet.com, with archived replays available for 90 days after each live event.

News Market Reaction

-10.53%

1 alert

-10.53% News Effect

-$21M Valuation Impact

$180M Market Cap

0.9x Rel. Volume

On the day this news was published, SGMT declined 10.53%, reflecting a significant negative market reaction. This price movement removed approximately $21M from the company's valuation, bringing the market cap to $180M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.

• Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY, on February 11, 2026, with a fireside chat at 10am ET (link here).
  
• Oppenheimer 36^th Annual Healthcare Life Sciences Conference on February 26, 2026, with a fireside chat at 9:20am ET (link here).
  

The Guggenheim and Oppenheimer fireside chats will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom is currently being tested in a Phase 1 PK clinical trial and is planned to be developed for cirrhotic patients living with F4-stage MASH. TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial. For additional information about Sagimet, please visit www.sagimet.com.

Investor Contact:
Joyce Allaire 
LifeSci Advisors 
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

FAQ

When is Sagimet (SGMT) presenting at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Sagimet will present on February 11, 2026 with a fireside chat at 10:00 AM ET. According to the company, the event takes place in New York and the live webcast will be available in the Investors & Media section at www.sagimet.com.

What time is Sagimet (SGMT) scheduled for the Oppenheimer 36th Annual Healthcare Life Sciences Conference?

Sagimet's fireside chat is scheduled for February 26, 2026 at 9:20 AM ET. According to the company, the session will be webcast and an archived replay will be posted on the company's Investors & Media webpage for 90 days after the live event.

Where can investors watch Sagimet (SGMT) fireside chats and for how long will replays be available?

Investors can watch live and archived replays in the Investors & Media section at www.sagimet.com. According to the company, archived replays of each fireside chat will remain available for 90 days following the live presentation.

Will Sagimet (SGMT) provide on-demand access to the Guggenheim and Oppenheimer presentations?

Yes. According to the company, both the Guggenheim and Oppenheimer fireside chats will be posted online with archived replay access. The company said each replay will be available for 90 days after the live event in the Investors & Media section.

How can shareholders prepare to view Sagimet (SGMT) events on February 11 and February 26, 2026?

Shareholders should visit www.sagimet.com ahead of the events to access the webcast links and registration details. According to the company, the Investors & Media section will host live streams and archived replays for 90 days after each event.